Diabetic kidney disease (DKD) affects 40% of individuals with diabetes and is the leading cause of chronic kidney disease worldwide. While the KDIGO guidelines have established quadruple therapy comprising renin-angiotensin system inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists as the cornerstone of DKD management, substantial phenotypic and molecular heterogeneity among patients limits the efficacy of standardized protocols. Emerging evidence highlights distinct DKD subtypes defined by inflammatory, metabolic, fibrotic, and vascular pathobiological pathways, which may warrant tailored therapeutic strategies. Novel biomarkers, including tubular injury markers, inflammatory mediators, and genetic variants such as APOL1, offer opportunities for phenotype-driven treatment. Multi-omic integration, encompassing genomics, transcriptomics, proteomics, and metabolomics, combined with machine learning algorithms, enables the identification of treatment-responsive phenotypes and supports clinical decision-making. Emerging therapeutic targets, including complement system inhibitors, ketone metabolism modulators, and JAK-STAT pathway inhibitors, have further expanded the precision medicine landscape in DKD management. Implementation challenges include biomarker standardization, healthcare infrastructure requirements, cost-effectiveness, regulatory validation, and equitable access to diverse populations. Addressing these barriers through multidisciplinary collaboration, point-of-care diagnostics, and inclusive clinical trials is essential for personalized DKD management. Goal-directed personalized DKD management represents a transformative paradigm with the potential to optimize outcomes, minimize adverse effects, and reduce long-term healthcare costs.
Gerry George Mathew (Thu,) studied this question.